2001
DOI: 10.1016/s0006-3223(01)01190-8
|View full text |Cite
|
Sign up to set email alerts
|

Echogenicity of substantia nigra determined by transcranial ultrasound correlates with severity of parkinsonian symptoms induced by neuroleptic therapy

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

3
46
0
3

Year Published

2005
2005
2017
2017

Publication Types

Select...
8

Relationship

2
6

Authors

Journals

citations
Cited by 102 publications
(52 citation statements)
references
References 14 publications
3
46
0
3
Order By: Relevance
“…10 Substantia nigra echogenicity was correlated to presynaptic dopaminergic dysfunction elicited by single photon emission computed tomography in patients with Parkinson disease 16 and with the severity of parkinsonism induced by neuroleptics in patients with schizophrenia. 17 However, there is still disagreement about how abnormal extension of substantia nigra echogenicity is related to the pathogenic substrate of Parkinson disease. Furthermore, the functional significance of increased substantia nigra echogenicity in children with ADHD is yet unknown.…”
Section: Discussionmentioning
confidence: 99%
“…10 Substantia nigra echogenicity was correlated to presynaptic dopaminergic dysfunction elicited by single photon emission computed tomography in patients with Parkinson disease 16 and with the severity of parkinsonism induced by neuroleptics in patients with schizophrenia. 17 However, there is still disagreement about how abnormal extension of substantia nigra echogenicity is related to the pathogenic substrate of Parkinson disease. Furthermore, the functional significance of increased substantia nigra echogenicity in children with ADHD is yet unknown.…”
Section: Discussionmentioning
confidence: 99%
“…SNH is less frequently encountered in essential tremor, vascular parkinsonism, multiple system atrophy and progressive supranuclear palsy while this echo feature occurs in most PD patients 1,4,5 . SNH can be found in a minority of healthy subjects (10%) and they are more likely to develop extrapyramidal signs and symptoms following administration of neuroleptic 1,2,5 .…”
Section: Discussionmentioning
confidence: 99%
“…Future longitudinal studies must address if SNH can help to identify PD patients at preclinical stages mainly if considered in conjunction with other nonmotor signs of PD, such as depression, olfactory dysfunction, neuropsychological deficits and idiopathic REM sleep behavior disorder 5 . If this idea is true, PD could be identified before manifestation of typical signs and symptoms, allowing development of neuroprotective therapies [1][2][3][4][5] .…”
Section: Case Reportmentioning
confidence: 99%
See 1 more Smart Citation
“…Considering the possibility of on-going neurodegeneration, these healthy individuals without a sign of parkinsonism but with SN+ were further investigated in several studies, which revealed that, (i) healthy individuals with SN+ may have nigrostriatal impairment detected by reduced presynaptic dopaminergic tracer uptake [9,10], (ii) show sub-clinical motor slowing [11,12], (iii) perform slightly worse in cognitive or olfaction tests [13,14] compared to individuals with normal SN echogenicity and (iv) are more prone to develop severe extrapyramidal symptoms after disposure to neuroleptic drugs [15]. Furthermore, healthy individuals with increased risk for PD, such as positive family history, asymptomatic carriers of mutations associated with PD [16,17] or REM sleep behavior disorder [18,19] also exhibited a higher rate of SN + compared to the ones without these risk and prodromal markers.…”
Section: Sn Hyperechogenicity As a Potential Premotor Markermentioning
confidence: 99%